Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d78cd2835221849f6a74e6349185819 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-28 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-204 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
1991-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94c45a8ba84f7d66271b2bcfbffc0dfc |
publicationDate |
1993-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-H05221871-A |
titleOfInvention |
Formulation of pharmacologically active and acid stable polypeptides |
abstract |
(57) [Summary] [Purpose] Preparation of pharmacologically active and acid-stable polypeptides in the form of injectable suspensions [Structure] Acid-stable polypeptides 0.1-50% by weight And the ratio of glycolide unit to lactide unit is 0 to 3, soluble in benzene and intrinsic viscosity (combined with benzene 1 g / 100 ml solution) 0.5 or less, or 50 to 99.9% by weight of polylactide insoluble in benzene and having an intrinsic viscosity (1 g / 100 ml solution dissolved in chloroform or dioxane) 0.09-4, A pharmacologically active compound in the form of an injectable suspension containing 1 to 50% by weight of a solid formulation in which the shaped body is ground to a fine particle size, together with 50 to 99% by weight of a liquid carrier suitable for mammalian injection. Acid stable polypeptide formulation. |
priorityDate |
1981-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |